Gut microbiome-based medical methodologies for early-stage disease prevention

Microbial Pathogenesis

Volumn 105, Issue , 2017, Pages 122-130

  Wang, Jing Zhang ^a   Du, Wen Tao ^a   Xu, Yan Li ^a   Cheng, Shu Zhen ^a   Liu, Zhi Jun ^a  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

Author keywords

Early stage diagnostic biomarker; Gut microbiome; Microbial culturomics; Microbial reconstruction; Systemic disorders; Therapeutic target

Indexed keywords

DOXYCYCLINE; REACTIVE OXYGEN METABOLITE; VANCOMYCIN;

BIFIDOBACTERIUM; CHILDHOOD; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DISEASE MARKER; DYSBIOSIS; ENVIRONMENTAL FACTOR; FECAL MICROBIOTA TRANSPLANTATION; GENETIC VARIATION; HUMAN; INTESTINE FLORA; INTESTINE INFECTION; LACTOBACILLUS; MICROBIAL COMMUNITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; GASTROINTESTINAL TRACT; MICROBIOLOGY; PREVENTIVE MEDICINE; PROCEDURES;

DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; PREVENTIVE MEDICINE;

EID: 85013831822     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2017.02.024     Document Type: Review

References (167)

1. [1] Gill, S.R., Pop, M., DeBoy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., Gordon, J.I., Relman, D.A., Fraser-Liggett, C.M., Nelson, K.E., Metagenomic analysis of the human distal gut microbiome. Science 312 (2006), 1355–1359.
2. [2] Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
3. [3] Scarpellini, E., Ianiro, G., Attili, F., Bassanelli, C., De Santis, A., Gasbarrini, A., The human gut microbiota and virome: potential therapeutic implications. Digest. Liver Dis. 47 (2015), 1007–1012.
4. [4] Ravindran, C., Varatharajan, G.R., Raju, R., Vasudevan, L., Anantha, S.R., Infection and pathogenecity of Myroides odoratimimus (NIOCR-12) isolated from the gut of grey mullet (Mugil cephalus (Linnaeus, 1758)). Microb. Pathog. 88 (2015), 22–28.
5. [5] Schulberg, J., De Cruz, P., Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Intern. Med. J. 46 (2016), 266–273.
6. [6] Nakatsu, G., Li, X.C., Zhou, H.K., Sheng, J.Q., Wong, S.H., Wu, W.K.K., Ng, S.C., Tsoi, H., Dong, Y.J., Zhang, N., He, Y.Q., Kang, Q., Cao, L., Wang, K.N., Zhang, J.W., Liang, Q.Y., Yu, J., Sung, J.J.Y., Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun., 6, 2015, 8727.
7. [7] Yang, T.W., Tsai, M.C., Wang, C.C., Chang, M.H., Chen, T.H., Lee, W.H., Huang, H.D., Jong, Y.J., Lin, C.C., The human gut microbiome profile in health and adenoma-carcinoma sequence. J. Gastroen. Hepatol., 30, 2015, 111.
8. [8] Till, H., Castellani, C., Moissl-Eichinger, C., Gorkiewicz, G., Singer, G., Disruptions of the intestinal microbiome in necrotizing enterocolitis, short bowel syndrome, and Hirschsprung's associated enterocolitis. Front. Microbiol., 6, 2015, 1154.
9. [9] Kelly, J.R., Kennedy, P.J., Cryan, J.F., Dinan, T.G., Clarke, G., Hyland, N., Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell Neurosci., 9, 2015, 392.
10. [10] Latorre, M., Krishnareddy, S., Freedberg, D.E., Microbiome as mediator: do systemic infections start in the gut?. World J. Gastroentero 21 (2015), 10486–10491.
11. [11] Jangi, S., Gandhi, R., Li, N., Von Glehn, F., Yan, R., Melo, K., Mazzola, M., Patel, B., Glanz, B., Cook, S., Stuart, F., Holden, J., Kivisakk, P., De Jager, P., Chitnis, T., Bakshi, R., Quintana, F., Gerber, G., Bry, L., Weiner, H., Alterations of the human gut microbiome in multiple sclerosis. Mult. Scler. J., 21, 2015 168–168.
12. [12] Van Houten, J.M., Wessells, R.J., Lujan, H.L., DiCarlo, S.E., My gut feeling says rest: increased intestinal permeability contributes to chronic diseases in high-intensity exercisers. Med. Hypotheses 85 (2015), 882–886.
13. [13] Heberling, C.A., Dhurjati, P.S., Sasser, M., Hypothesis for a systems connectivity model of autism spectrum disorder pathogenesis: links to gut bacteria, oxidative stress, and intestinal permeability. Med. Hypotheses 80 (2013), 264–270.
14. [14] Moyano-Porcile, V., Olavarria-Ramirez, L., Gonzalez-Arancibia, C., Bravo, J.A., Julio-Pieper, M., Short-term effects of Poly(I: C) on gut permeability. Pharmacol. Res. 101 (2015), 130–136.
15. [15] Larsen, P.E., Dai, Y., Metabolome of human gut microbiome is predictive of host dysbiosis. Gigascience, 4, 2015, 42.
16. [16] Salzberger, B., Rauscher, C., The microbiome of the gut in critically ill patients. Med. Klin. Intensivmed. Notfmed 110 (2015), 521–525.
17. [17] D'Argenio, V., Salvatore, F., The role of the gut microbiome in the healthy adult status. Clin. Chim. ACTA 451 (2015), 97–102.
18. [18] Tuddenham, S., Sears, C.L., The intestinal microbiome and health. Curr. Opin. Infect. Dis. 28 (2015), 464–470.
19. [19] Zhang, D.X., Huang, Y.P., Ye, D.Y., Intestinal dysbiosis: an emerging cause of pregnancy complications?. Med. Hypotheses 84 (2015), 223–226.
20. [20] Tremellen, K., Pearce, K., Dysbiosis of gut microbiota (DOGMA) - a novel theory for the development of polycystic ovarian syndrome. Med. Hypotheses 79 (2012), 104–112.
21. [21] Backhed, F., Roswall, J., Peng, Y.Q., Feng, Q., Jia, H.J., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H.L., Zhong, H.Z., Khan, M.T., Zhang, J.F., Li, J.H., Xiao, L., Al-Aama, J., Zhang, D.Y., Lee, Y.S., Kotowska, D., Colding, C., Tremaroli, V., Yin, Y., Bergman, S., Xu, X., Madsen, L., Kristiansen, K., Dahlgren, J., Jun, W., Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host. Microbe 17 (2015), 690–703.
22. [22] Mueller, N.T., Shin, H., Pizoni, A., Werlang, I.C., Matte, U., Goldani, M.Z., Goldani, H.A.S., Dominguez-Bello, M.G., Birth mode-dependent association between pre-pregnancy maternal weight status and the neonatal intestinal microbiome. Sci. Rep-UK, 6, 2016, 23133.
23. [23] Astbury, S., Mostyn, A., Symonds, M.E., Bell, R.C., Nutrient availability, the microbiome, and intestinal transport during pregnancy. Appl. Physiol. Nutr. Me 40 (2015), 1100–1106.
24. [24] Madan, J.C., Hoen, A.G., Lundgren, S.N., Farzan, S.F., Cottingham, K.L., Morrison, H.G., Sogin, M.L., Li, H.Z., Moore, J.H., Karagas, M.R., Association of cesarean delivery and formula supplementation with the intestinal microbiome of 6-week-old infants. Jama Pediatr. 170 (2016), 212–219.
25. [25] Meropol, S.B., Edwards, A., Development of the infant intestinal microbiome: a bird's eye view of a complex process. Birth. Defects. Res. C 105 (2015), 228–239.
26. [26] Mastromarino, P., Capobianco, D., Miccheli, A., Pratico, G., Campagna, G., Laforgia, N., Capursi, T., Baldassarre, M.E., Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacol. Res. 95–96 (2015), 63–70.
27. [27] Fernandez, L., Langa, S., Martin, V., Maldonado, A., Jimenez, E., Martin, R., Rodriguez, J.M., The human milk microbiota: origin and potential roles in health and disease. Pharmacol. Res. 69 (2013), 1–10.
28. [28] Praveen, P., Jordan, F., Priami, C., Morine, M.J., The role of breast-feeding in infant immune system: a systems perspective on the intestinal microbiome. Microbiome, 3, 2015 Unsp. 41.
29. [29] Houck, K.M., Thompson, A.L., Sorensen, M.V., Childhood intestinal health, immune function and the gut microbiome in galapagos, ecuador. Am. J. Hum. Biol., 28, 2016, 281.
30. [30] Cook, M.D., Allen, J.M., Pence, B.D., Wallig, M.A., Gaskins, H.R., White, B.A., Woods, J.A., Exercise and gut immune function: evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. Immunol. Cell Biol. 94 (2016), 158–163.
31. [31] Omenetti, S., Pizarro, T.T., The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front. Immunol, 6, 2015 Unsp. 639.
32. [32] Levy, J., Cacheux, W., Bara, M.A., L'Hermitte, A., Lepage, P., Fraudeau, M., Trentesaux, C., Lemarchand, J., Durand, A., Crain, A.M., Marchiol, C., Renault, G., Dumont, F., Letourneur, F., Delacres, M., Schmitt, A., Terris, B., Perret, C., Chamaillard, M., Couty, J.P., Romagnolo, B., Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat. Cell Biol. 17 (2015), 1062–1073.
33. [33] Kazama, I., Roles of lymphocyte Kv1.3-channels in gut mucosal immune system: novel therapeutic implications for inflammatory bowel disease. Med. Hypotheses 85 (2015), 61–63.
34. [34] Weiss, S.T., Litonjua, A.A., Vitamin D, the gut microbiome, and the hygiene hypothesis how does asthma begin?. Am. J. Resp. Crit. Care 191 (2015), 492–493.
35. [35] Liu, H., Guo, X.W., Gooneratne, R., Lai, R.F., Zeng, C., Zhan, F.B., Wang, W.M., The gut microbiome and degradation enzyme activity of wild freshwater fishes influenced by their trophic levels. Sci. Rep-UK, 6, 2016, 24340.
36. [36] Bhattacharya, T., Ghosh, T.S., Mande, S.S., Global profiling of carbohydrate active enzymes in human gut microbiome. Plos One, 10, 2015, e0142038.
37. [37] Antharam, V.C., McEwen, D.C., Garrett, T.J., Dossey, A.T., Li, E.C., Kozlov, A.N., Mesbah, Z., Wang, G.P., An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in Clostridium difficile infection. Plos One, 11, 2016, e0148824.
38. [38] Fu, J.Y., Bonder, M.J., Cenit, M.C., Tigchelaar, E.F., Maatman, A., Dekens, J.A.M., Brandsma, E., Marczynska, J., Imhann, F., Weersma, R.K., Franke, L., Poon, T.W., Xavier, R.J., Gevers, D., Hofker, M.H., Wijmenga, C., Zhernakova, A., The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 117 (2015), 817–824.
39. [39] Kao, C.C., Cope, J.L., Hsu, J.W., Dwarkanath, P., Karnes, J.M., Luna, R.A., Hollister, E.B., Thame, M.M., Kurpad, A.V., Jahoor, F., The microbiome, intestinal function, and arginine metabolism of healthy indian women are different from those of american and jamaican women. J. Nutr. 146 (2016), 706–713.
40. [40] Wilson, A., McLean, C., Kim, R.B., Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr. Opin. Lipidol. 27 (2016), 148–154.
41. [41] Foucault, A.S., Even, P., Lafont, R., Dioh, W., Veillet, S., Tome, D., Huneau, J.F., Hermier, D., Quignard-Boulange, A., Quinoa extract enriched in 20-hydroxyecdysone affects energy homeostasis and intestinal fat absorption in mice fed a high-fat diet. Physiol. Behav. 128 (2014), 226–231.
42. [42] McCutcheon, J.E., The role of dopamine in the pursuit of nutritional value. Physiol. Behav. 152 (2015), 408–415.
43. [43] Steimle, A., Autenrieth, I.B., Frick, J.S., Structure and function: lipid A modifications in commensals and pathogens. Int. J. Med. Microbiol. 306 (2016), 290–301.
44. [44] Blanton, L.V., Charbonneau, M.R., Salih, T., Barratt, M.J., Venkatesh, S., Ilkaveya, O., Subramanian, S., Manary, M.J., Trehan, I., Jorgensen, J.M., Fan, Y.-m., Henrissat, B., Leyn, S.A., Rodionov, D.A., Osterman, A.L., Maleta, K.M., Newgard, C.B., Ashorn, P., Dewey, K.G., Gordon, J.I., Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science, 351, 2016, aad3311.
45. [45] Charbonneau, M.R., O'Donnell, D., Blanton, L.V., Totten, S.M., Davis, J.C.C., Barratt, M.J., Cheng, J.Y., Guruge, J., Talcott, M., Bain, J.R., Muehlbauer, M.J., Ilkayeva, O., Wu, C., Struckmeyer, T., Barile, D., Mangani, C., Jorgensen, J., Fan, Y.M., Maleta, K., Dewey, K.G., Ashorn, P., Newgard, C.B., Lebrilla, C., Mills, D.A., Gordon, J.I., Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 164 (2016), 859–871.
46. [46] Schwarzer, M., Makki, K., Storelli, G., Machuca-Gayet, I., Srutkova, D., Hermanova, P., Martino, M.E., Balmand, S., Hudcovic, T., Heddi, A., Rieusset, J., Kozakova, H., Vidal, H., Leulier, F., Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition. Science 351 (2016), 854–857.
47. [47] Subramanian, S., Huq, S., Yatsunenko, T., Haque, R., Mahfuz, M., Alam, M.A., Benezra, A., DeStefano, J., Meier, M.F., Muegge, B.D., Barratt, M.J., VanArendonk, L.G., Zhang, Q.Y., Province, M.A., Petri, W.A., Ahmed, T., Gordon, J.I., Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 510 (2014), 417–421.
48. [48] Rubel, M., Hansen, M.E.B., Bailey, A., Bittinger, K., Laughlin, A., Beggs, W.R., Ranciaro, A., Thompson, S.R., Bushman, F.D., Tishkoff, S.A., Environmental and dietary factors shaping african gut microbiomes. Am. J. Phys. Anthropol., 159, 2016, 274.
49. [49] Preidis, G.A., Ajami, N.J., Wong, M.C., Bessard, B.C., Conner, M.E., Petrosino, J.F., Composition and function of the undernourished neonatal mouse intestinal microbiome. J. Nutr. Biochem. 26 (2015), 1050–1057.
50. [50] Pepino, M.Y., Metabolic effects of non-nutritive sweeteners. Physiol. Behav. 152 (2015), 450–455.
51. [51] Burke, M.V., Small, D.M., Physiological mechanisms by which non-nutritive sweeteners may impact body weight and metabolism. Physiol. Behav. 152 (2015), 381–388.
52. [52] Zhernakova, A., Kurilshikov, A., Bonder, M.J., Tigchelaar, E.F., Schirmer, M., Vatanen, T., Mujagic, Z., Vila, A.V., Falony, G., Vieira-Silva, S., Wang, J., Imhann, F., Brandsma, E., Jankipersadsing, S.A., Joossens, M., Cenit, M.C., Deelen, P., Swertz, M.A., Weersma, R.K., Feskens, E.J.M., Netea, M.G., Gevers, D., Jonkers, D., Franke, L., Aulchenko, Y.S., Huttenhower, C., Raes, J., Hofker, M.H., Xavier, R.J., Wijmenga, C., Fu, J., Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352 (2016), 565–569.
53. [53] Chu, D., Antony, K., Ma, J., Prince, A., Moller, M., Boggan, B., Aagaard, K., A maternal high fat diet (HFD) during gestation alters the neonatal gut microbiome in a human population based longitudinal cohort. Am. J. Obstet. Gynecol., 214, 2016, S79.
54. [54] Prince, A., Ma, J., Baquero, K., Blundell, P., Takahashi, D., Grove, K., Aagaard, K., Probiotics alter the intestinal microbiome but do not prevent high fat diet dysbiosis in primates. Am. J. Obstet. Gynecol., 214, 2016, S44.
55. [55] Amato, K.R., Yeoman, C.J., Cerda, G., Schmitt, C.A., Cramer, J.D., Miller, M.E.B., Gomez, A., Turner, T.R., Wilson, B.A., Stumpf, R.M., Nelson, K.E., White, B.A., Knight, R., Leigh, S.R., Variable responses of human and non-human primate gut microbiomes to a Western diet. Microbiome, 3, 2015, 53.
56. [56] Glade, M.J., Meguid, M.M., A glance at… dietary emulsifiers, the human intestinal mucus and microbiome, and dietary fiber. Nutrition 32 (2016), 609–614.
57. [57] Kirpich, I.A., Petrosino, J., Ajami, N., Feng, W.K., Wang, Y.H., Liu, Y.L., Beier, J.I., Barve, S.S., Yin, X.M., Wei, X.L., Zhang, X., McClain, C.J., Saturated and unsaturated dietary fats differentially modulate ethanol-induced changes in gut microbiome and metabolome in a mouse model of alcoholic liver disease. Am. J. Pathol. 186 (2016), 765–776.
58. [58] Monteagudo-Mera, A., Arthur, J.C., Jobin, C., Keku, T., Bruno-Barcena, J.M., Azcarate-Peril, M.A., High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome. Benef. Microbes 7 (2016), 247–264.
59. [59] Kirpich, I., Feng, W.K., Barve, S., Yin, X.M., Wei, X.L., Zhang, X., McClain, C.J., Alterations of gut microbiome and metabolome caused by ethanol and unsaturated fat diet were prevented by dietary saturated fat in a mouse model of alcoholic liver disease. Hepatology 62 (2015), 267A–268A.
60. [60] Kim, J.E., Lillehoj, H.S., Hong, Y.H., Kim, G.B., Lee, S.H., Lillehoj, E.P., Bravo, D.M., Dietary capsicum and curcuma longa oleoresins increase intestinal microbiome and necrotic enteritis in three commercial broiler breeds. Res. Vet. Sci. 102 (2015), 150–158.
61. [61] Turnbaugh, P., Contributions of the human gut microbiome to drug metabolism. Drug Metab. Rev., 47, 2015, 11.
62. [62] Yip, L.Y., Lee, S.H., Hong, Y.S., Chan, J.M.X., Koh, E.Y., Aw, C.C., Chen, W.S., Browne, E., Mahendran, R., Lee, Y.K., Chan, E.C.Y., The gut microbiome: implications in tacrine-induced transaminitis. Drug Metab. Rev. 47 (2015), 36–37.
63. [63] Schulz, C., Schutte, K., Kropf, S., Schmitt, F.C., Vasapolli, R., Kliegis, L.M., Riegger, A., Malfertheiner, P., RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Trials, 17, 2016, 111.
64. [64] Mardinoglu, A., Boren, J., Smith, U., Confounding effects of metformin on the human gut microbiome in type 2 diabetes. Cell Metab. 23 (2016), 10–12.
65. [65] Fornai, M., Antonioli, L., Pellegrini, C., Colucci, R., Sacco, D., Tirotta, E., Natale, G., Bartalucci, A., Flaibani, M., Renzulli, C., Ghelardi, E., Blandizzi, C., Scarpignato, C., Small bowel protection against NSAID-injury in rats: effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacol. Res. 104 (2016), 186–196.
66. [66] Wilding, L.A., Bassis, C.M., Walacavage, K., Hashway, S., Leroueil, P.R., Morishita, M., Maynard, A.D., Philbert, M.A., Bergin, I.L., Repeated dose (28-day) administration of silver nanoparticles of varied size and coating does not significantly alter the indigenous murine gut microbiome. Nanotoxicology 10 (2016), 513–520.
67. [67] Clooney, A.G., Bernstein, C.N., Leslie, W.D., Vagianos, K., Sargent, M., Laserna-Mendieta, E.J., Claesson, M.J., Targownik, L.E., A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharm. Ther. 43 (2016), 974–984.
68. [68] Imhann, F., Bonder, M.J., Vila, A.V., Fu, J.Y., Mujagic, Z., Vork, L., Tigchelaar, E.F., Jankipersadsing, S.A., Cenit, M.C., Harmsen, H.J.M., Dijkstra, G., Franke, L., Xavier, R.J., Jonkers, D., Wijmenga, C., Weersma, R.K., Zhernakova, A., Proton pump inhibitors affect the gut microbiome. Gut 65 (2016), 740–748.
69. [69] Langhendries, J.P., Allegaert, K., Van den Anker, J.N., Veyckemans, F., Smets, F., Possible effects of repeated exposure to ibuprofen and acetaminophen on the intestinal immune response in young infants. Med. Hypotheses 87 (2016), 90–96.
70. [70] Cai, S.P., Zhou, X.M., Yan, N.H., Liu, X.Y., Li, X.H., Possible mechanism for the gastro-intestinal adverse effects upon topical application of Prostaglandin F-2 alpha analogs. Med. Hypotheses 80 (2013), 32–35.
71. [71] Raymond, F., Ouameur, A.A., Deraspe, M., Iqbal, N., Gingras, H., Dridi, B., Leprohon, P., Plante, P.L., Giroux, R., Berube, E., Frenette, J., Boudreau, D.K., Simard, J.L., Chabot, I., Domingo, M.C., Trottier, S., Boissinot, M., Huletsky, A., Roy, P.H., Ouellette, M., Bergeron, M.G., Corbeil, J., The initial state of the human gut microbiome determines its reshaping by antibiotics. Isme. J. 10 (2016), 707–720.
72. [72] Lewis, J.D., Chen, E.Z., Baldassano, R.N., Otley, A.R., Griffiths, A.M., Lee, D., Bittinger, K., Bailey, A., Friedman, E.S., Hoffmann, C., Albenberg, L., Sinha, R., Compher, C., Gilroy, E., Nessel, L., Grant, A., Chehoud, C., Li, H.Z., Wu, G.D., Bushman, F.D., Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host. Microbe 18 (2015), 489–500.
73. [73] Rahmoune, H., Boutrid, N., Amrane, M., Bioud, B., Antibiotics, intestinal dysbiosis and risk of celiac disease. Dig. Liver Dis., 49, 2017, 106, 10.1016/j.dld.2016.09.004.
74. [74] Karimaei, S., Sadeghi, J., Asadian, M., Esghaei, M., Pourshafie, M.R., Talebi, M., Antibacterial potential and genetic profile of Enterococcus faecium strains isolated from human normal flora. Microb. Pathog. 96 (2016), 67–71.
75. [75] Brown, K., Godovannyi, A., Ma, C.X., Zhang, Y.Q., Ahmadi-Vand, Z., Dai, C.B., Gorzelak, M.A., Chan, Y., Chan, J.M., Lochner, A., Dutz, J.P., Vallance, B.A., Gibson, D.L., Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. Isme. J. 10 (2016), 321–332.
76. [76] Yallapragada, S.G., Nash, C.B., Robinson, D.T., Early-life exposure to antibiotics, alterations in the intestinal microbiome, and risk of metabolic disease in children and adults. Pediatr. Ann. 44 (2015), E265–E269.
77. [77] Candon, S., Perez-Arroyo, A., Marquet, C., Valette, F., Foray, A.P., Pelletier, B., Milani, C., Ventura, M., Bach, J.F., Chatenoud, L., Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. Plos One, 10, 2015, e0125448.
78. [78] Bazett, M., Bergeron, M.E., Haston, C.K., Streptomycin treatment alters the intestinal microbiome, pulmonary T cell profile and airway hyperresponsiveness in a cystic fibrosis mouse model. Sci. Rep-UK, 6, 2016, 19189.
79. [79] Singh, A.K., Yang, I., Riederer, B., Fang, X., Suerbaum, S., Seidler, U., SLC26a3 (DRA)-deficient mice display low surface pH, loss of firmly adherent mucus layer, altered colonic microbiome, and intestinal inflammation. ACTA Physiol., 215, 2015 33–33.
80. [80] Gloux, K., Anba-Mondoloni, J., Unique beta-glucuronidase locus in gut microbiomes of Crohn's disease patients and unaffected first-degree relatives. Plos One, 11, 2016, e0148291.
81. [81] Inserra, A., Lewis, M., Mastronardi, C., Rogers, G., Leong, L., Choo, J., Wong, M.L., Licinio, J., Inflammasome signaling affects anxiety- and depressive-like behaviors and gut microbiome composition. Neuropsychopharmacol 40 (2015), S311–S312.
82. [82] Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J.T., Spector, T.D., Clark, A.G., Ley, R.E., Human genetics shape the gut microbiome. Cell 159 (2014), 789–799.
83. [83] Ni, Y.Q., Li, J., Panagiotou, G., A molecular-level landscape of diet-gut microbiome interactions: toward dietary interventions targeting bacterial genes. Mbio, 6, 2015 e01263–15.
84. [84] Bengtsson-Palme, J., Angelin, M., Huss, M., Kjellqvist, S., Kristiansson, E., Palmgren, H., Larsson, D.G.J., Johanssone, A., The human gut microbiome as a transporter of antibiotic resistance genes between continents. Antimicrob. Agents. Ch. 59 (2015), 6551–6560.
85. [85] Shukla, S.K., Cook, D., Meyer, J., Vernon, S.D., Le, T., Clevidence, D., Robertson, C.E., Schrodi, S.J., Yale, S., Frank, D.N., Changes in gut and plasma microbiome following exercise challenge in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Plos One, 10, 2015, e0145453.
86. [86] Zhang, S.B., Jin, Y.X., Zeng, Z.Y., Liu, Z.Z., Fu, Z.W., Subchronic exposure of mice to cadmium perturbs their hepatic energy metabolism and gut microbiome. Chem. Res. Toxicol. 28 (2015), 2000–2009.
87. [87] Sankaranarayanan, K., Ozga, A.T., Warinner, C., Tito, R.Y., Obregon-Tito, A.J., Xu, J.W., Gaffney, P.M., Jervis, L.L., Cox, D., Stephens, L., Foster, M., Tallbull, G., Spicer, P., Lewis, C.M., Gut microbiome diversity among cheyenne and arapaho individuals from western Oklahoma. Curr. Biol. 25 (2015), 3161–3169.
88. [88] Frankenfeld, C.L., Sikaroodi, M., Lamb, E., Shoemaker, S., Gillevet, P.M., High-intensity sweetener consumption and gut microbiome content and predicted gene function in a cross-sectional study of adults in the United States. Ann. Epidemiol. 25 (2015), 736–742.
89. [89] Johanesen, P.A., Mackin, K.E., Hutton, M.L., Awad, M.M., Larcombe, S., Amy, J.M., Lyras, D., Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes-Basel 6 (2015), 1347–1360.
90. [90] Zaiss, M.M., Harris, N.L., Interactions between the intestinal microbiome and helminth parasites. Parasite. Immunol. 38 (2016), 5–11.
91. [91] Sheng, Y., Fan, F.X., Jensen, O., Zhong, Z.T., Kan, B.A., Wang, H., Zhu, J., Dual zinc transporter systems in vibrio cholerae promote competitive advantages over gut microbiome. Infect. Immun. 83 (2015), 3902–3908.
92. [92] Rodriguez, C., Taminiau, B., Van Broeck, J., Delmee, M., Daube, G., Clostridium difficile infection and intestinal microbiota interactions. Microb. Pathog. 89 (2015), 201–209.
93. [93] Tyler, A.D., Kirsch, R., Milgrom, R., Stempak, J.M., Kabakchiev, B., Silverberg, M.S., Microbiome heterogeneity characterizing intestinal tissue and inflammatory bowel disease phenotype. Inflamm. Bowel. Dis. 22 (2016), 807–816.
94. [94] Forbes, J.D., Van Domselaar, G., Bernstein, C.N., Microbiome survey of the inflamed and noninflamed gut at different compartments within the gastrointestinal tract of inflammatory bowel disease patients. Inflamm. Bowel. Dis. 22 (2016), 817–825.
95. [95] Skowron, K.B., Lapin, B., Rubin, M., Hurst, R.D., Rubin, D.T., Hyman, N.H., Umanskiy, K., Clostridium difficile infection in ulcerative colitis: can alteration of the gut-associated microbiome contribute to pouch failure?. Inflamm. Bowel. Dis. 22 (2016), 902–911.
96. [96] Rayes, A., Morrow, A.L., Payton, L.R., Lake, K.E., Lane, A., Davies, S.M., A genetic modifier of the gut microbiome influences the risk of graft-versus-host disease and bacteremia after hematopoietic stem cell transplantation. Biol. Blood. Marrow. Tr. 22 (2016), 418–422.
97. [97] Haghikla, A., Landmesser, U., Emerging role of the gut microbiome for cardiovascular disease Genetic-environmental interaction paradigm of cardiovascular disease. Eur. Heart J. 36 (2015), 3130–3132.
98. [98] Nagatomo, Y., Tang, W.H.W., Intersections between microbiome and heart failure: revisiting the gut hypothesis. J. Card. Fail. 21 (2015), 973–980.
99. [99] Witjes, J.J., van Raalte, D.H., Nieuwdorp, M., About the gut microbiome as a pharmacological target in atherosclerosis. Eur. J. Pharmacol. 763 (2015), 75–78.
100. [100] Durgan, D.J., Ganesh, B.P., Cope, J.L., Ajami, N.J., Phillips, S.C., Petrosino, J.F., Hollister, E.B., Bryan, R.M., Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67 (2016), 469–474.
101. [101] Bahr, S.M., Weidemann, B.J., Castro, A.N., Walsh, J.W., Deleon, O., Burnett, C.M.L., Pearson, N.A., Murry, D.J., Grobe, J.L., Kirby, J.R., Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. Ebiomedicine 2 (2015), 1725–1734.
102. [102] Peat, C.M., Kleiman, S.C., Bulik, C.M., Carroll, I.M., The intestinal microbiome in bariatric surgery patients. Eur. Eat. Disord. Rev. 23 (2015), 496–503.
103. [103] Barlow, G.M., Yu, A., Mathur, R., Role of the gut microbiome in obesity and diabetes mellitus. Nutr. Clin. Pract. 30 (2015), 787–797.
104. [104] Hu, C.Y., Wong, F.S., Wen, L., Type 1 diabetes and gut microbiota: friend or foe?. Pharmacol. Res. 98 (2015), 9–15.
105. [105] Angelakis, E., Weight gain by gut microbiota manipulation in productive animals. Microb. Pathog., 2016, 10.1016/j.micpath.2016.11.002 (in press).
106. [106] de La Serre, C.B., de Lartigue, G., Raybould, H.E., Chronic exposure to Low dose bacterial lipopolysaccharide inhibits leptin signaling in vagal afferent neurons. Physiol. Behav. 139 (2015), 188–194.
107. [107] Flowers, S.A., Ellingrod, V.L., The microbiome in mental health: potential contribution of gut microbiota in disease and pharmacotherapy management. Pharmacotherapy 35 (2015), 910–916.
108. [108] Mahony, S.M.O., Stilling, R.M., Dinan, T.G., Cryan, J.F., The microbiome and childhood diseases: focus on brain-gut axis. Birth. Defects. Res. C 105 (2015), 296–313.
109. [109] Ghaisas, S., Maher, J., Kanthasamy, A., Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol. Ther. 158 (2016), 52–62.
110. [110] Cong, X.M., Henderson, W.A., Graf, J., McGrath, J.M., Early life experience and gut microbiome the brain-gut-microbiota signaling system. Adv. Neonat. Care 15 (2015), 314–323.
111. [111] Kelly, J.R., Gut microbiome alterations in major depressive disorder: relevance to pathophysiology. Eur. Neuropsychopharm, 25, 2015, S456.
112. [112] Foster, J., Gut-brain communication: how the microbiome influences anxiety and depression. Eur. Neuropsychopharm, 25, 2015, S141.
113. [113] Cryan, J.F., Dinan, T.G., The microbiome-gut-brain axis: how bacteria can cause mood and psychotic disorders. Eur. Neuropsychopharm 25 (2015), S140–S141.
114. [114] Sherwin, E., Rea, K., Dinan, T.G., Cryan, J.F., A gut (microbiome) feeling about the brain. Curr. Opin. Gastroen 32 (2016), 96–102.
115. [115] Weston, B., Fogal, B., Cook, D., Dhurjati, P., An agent-based modeling framework for evaluating hypotheses on risks for developing autism: effects of the gut microbial environment. Med. Hypotheses 84 (2015), 395–401.
116. [116] Rees, J.C., Obsessive-compulsive disorder and gut microbiota dysregulation. Med. Hypotheses 82 (2014), 163–166.
117. [117] Downs, R., Perna, J., Vitelli, A., Cook, D., Dhurjati, P., Model-based hypothesis of gut microbe populations and gut/brain barrier permeabilities in the development of regressive autism. Med. Hypotheses 83 (2014), 649–655.
118. [118] Ritz, N.L., Burnett, B.J., Setty, P., Reinhart, K.M., Wilson, M.R., Alcock, J., Singh, S.B., Barton, L.L., Lin, H.C., Sulfate-reducing bacteria impairs working memory in mice. Physiol. Behav. 157 (2016), 281–287.
119. [119] Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., Ostatnikova, D., Gastrointestinal microbiota in children with autism in Slovakia. Physiol. Behav. 138 (2015), 179–187.
120. [120] Jorgensen, B.P., Krych, L., Pedersen, T.B., Plath, N., Redrobe, J.P., Hansen, A.K., Nielsen, D.S., Pedersen, C.S., Larsen, C., Sorensen, D.B., Investigating the long-term effect of subchronic phencyclidine-treatment on novel object recognition and the association between the gut microbiota and behavior in the animal model of schizophrenia. Physiol. Behav. 141 (2015), 32–39.
121. [121] Dubin, K., Callahan, M.K., Ren, B.Y., Khanin, R., Viale, A., Ling, L.L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E.G., Wolchok, J.D., Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun., 7, 2016, 10391.
122. [122] Paul, B., Barnes, S., Demark-Wahnefried, W., Morrow, C., Salvador, C., Skibola, C., Tollefsbol, T.O., Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin. Epigenetics, 7, 2015, 112.
123. [123] Prince, B.T., Mandel, M.J., Nadeau, K., Singh, A.M., Gut microbiome and the development of food allergy and allergic disease. Pediatr. Clin. N. Am. 62 (2015), 1479–1492.
124. [124] Ben Ya ' acov, A., Lichtenstein, Y., Zolotarov, L., Ilan, Y., The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis. Bmc. Gastroenterol, 15, 2015, 154.
125. [125] Krisko, T.I., Nicholls, H.T., Leclair, K.B., Banks, A.S., Cohen, D.E., Regulation of adaptive thermogenesis by the gut microbiome: implications for non-alcoholic fatty liver disease (NAFLD) pathogenesis. Hepatology, 62, 2015 645A.
126. [126] Aqel, B., DiBaise, J.K., Role of the gut microbiome in nonalcoholic fatty liver disease. Nutr. Clin. Pract. 30 (2015), 780–786.
127. [127] Ramezani, A., Massy, Z.A., Meijers, B., Evenepoel, P., Vanholder, R., Raj, D.S., Role of the gut microbiome in uremia: a potential therapeutic target. Am. J. Kidney. Dis. 67 (2016), 483–498.
128. [128] Oyri, S.F., Muzes, G., Sipos, F., Dysbiotic gut microbiome: a key element of Crohn's disease. Comp. Immunol. Microb. 43 (2015), 36–49.
129. [129] Million, M., Diallo, A., Raoult, D., Gut microbiota and malnutrition. Microb. Pathogenesis, 2016, 10.1016/j.micpath.2016.02.003 (in press).
130. [130] Million, M., Alou, M.T., Khelaifia, S., Bachar, D., Lagier, J.C., Dione, N., Brah, S., Hugon, P., Lombard, V., Armougom, F., Fromonot, J., Robert, C., Michelle, C., Diallo, A., Fabre, A., Guieu, R., Sokhna, C., Henrissat, B., Parola, P., Raoult, D., Increased gut redox and depletion of anaerobic and methanogenic prokaryotes in severe acute malnutrition. Sci. Rep-UK, 6, 2016, 26051.
131. [131] Qiao, Y., Sun, J., Ding, Y.Y., Le, G.W., Shi, Y.H., Alterations of the gut microbiota in high-fat diet mice is strongly linked to oxidative stress. Appl. Microbiol. Biot. 97 (2013), 1689–1697.
132. [132] Murtaza, N., Baboota, R.K., Jagtap, S., Singh, D.P., Khare, P., Sarma, S.M., Podili, K., Alagesan, S., Chandra, T.S., Bhutani, K.K., Boparai, R.K., Bishnoi, M., Kondepudi, K.K., Finger millet bran supplementation alleviates obesity-induced oxidative stress, inflammation and gut microbial derangements in high-fat diet-fed mice. Brit. J. Nutr. 112 (2014), 1447–1458.
133. [133] Engen, P.A., Green, S.J., Voigt, R.M., Forsyth, C.B., Keshavarzian, A., The gastrointestinal microbiome alcohol effects on the composition of intestinal microbiota. Alcohol Research-Current Rev. 37 (2015), 223–236.
134. [134] Tan, C.Q., Wei, H.K., Ao, J.T., Long, G., Peng, J., Inclusion of konjac flour in the gestation diet changes the gut microbiota, alleviates oxidative stress, and improves insulin sensitivity in sows. Appl. Environ. Microb. 82 (2016), 5899–5909.
135. [135] Dias, V., Junn, E., Mouradian, M.M., The role of oxidative stress in Parkinson's disease. J. Park. Dis. 3 (2013), 461–491.
136. [136] Small, D.M., Coombes, J.S., Bennett, N., Johnson, D.W., Gobe, G.C., Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 17 (2012), 311–321.
137. [137] Hybertson, B.M., Gao, B.F., Bose, S.K., McCord, J.M., Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Asp. Med. 32 (2011), 234–246.
138. [138] Yan, M.H., Wang, X.L., Zhu, X.W., Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free. Radic. Bio. Med. 62 (2013), 90–101.
139. [139] Tang, D.L., Kang, R., Zeh, H.J., Lotze, M.T., High-mobility group box 1, oxidative stress, and disease. Antioxid. Redox. Sign 14 (2011), 1315–1335.
140. [140] Drummond, G.R., Selemidis, S., Griendling, K.K., Sobey, C.G., Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10 (2011), 453–471.
141. [141] Leclercq, S., Forsythe, P., Bienenstock, J., Posttraumatic stress disorder: does the gut microbiome hold the key?. Can. J. Psychiat 61 (2016), 204–213.
142. [142] Yap, T.W.C., Gan, H.M., Lee, Y.P., Leow, A.H.R., Azmi, A.N., Francois, F., Perez-Perez, G.I., Loke, M.F., Goh, K.L., Vadivelu, J., Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. Plos One, 11, 2016, e0151893.
143. [143] Song, H., Yoo, Y., Hwang, J., Na, Y.C., Kim, H.S., Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J. Allergy Clin. Immun. 137 (2016), 852–860.
144. [144] Donia, M.S., Cimermancic, P., Schulze, C.J., Brown, L.C.W., Martin, J., Mitreva, M., Clardy, J., Linington, R.G., Fischbach, M.A., A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158 (2014), 1402–1414.
145. [145] Demehri, F.R., Barrett, M., Teitelbaum, D.H., Changes to the intestinal microbiome with parenteral nutrition: review of a murine model and potential clinical implications. Nutr. Clin. Pract. 30 (2015), 798–806.
146. [146] Kim, H.J., Li, H., Collins, J.J., Ingber, D.E., Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E7–E15.
147. [147] Eiseman, B., Silen, W., Bascom, G.S., Kauvar, A.J., Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
148. [148] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J., Tijssen, J.G.P., Speelman, P., Dijkgraaf, M.G.W., Keller, J.J., Duodenal infusion of donor feces for recurrent clostridium difficile. New Engl. J. Med. 368 (2013), 407–415.
149. [149] Rajpal, D.K., Klein, J.L., Mayhew, D., Boucheron, J., Spivak, A.T., Kumar, V., Ingraham, K., Paulik, M., Chen, L.H., Van Horn, S., Thomas, E., Sathe, G., Livi, G.P., Holmes, D.J., Brown, J.R., Selective spectrum antibiotic modulation of the gut microbiome in obesity and diabetes rodent models. Plos One, 10, 2015, e0145499.
150. [150] Santiago-Rodriguez, T.M., Fornaciari, G., Luciani, S., Dowd, S.E., Toranzos, G.A., Marota, I., Cano, R.J., Gut microbiome of an 11th century AD pre-columbian andean mummy. Plos One, 10, 2015, e0138135.
151. [151] Jayasinghe, T.N., Chiavaroli, V., Holland, D.J., Cutfield, W.S., O'Sullivan, J.M., The new era of treatment for obesity and metabolic disorders: evidence and expectations for gut microbiome transplantation. Front. Cell Infect. Mi, 6, 2016, 15.
152. [152] Garrido-Mesa, J., Algieri, F., Rodriguez-Nogales, A., Utrilla, M.P., Rodriguez-Cabezas, M.E., Zarzuelo, A., Ocete, M.A., Garrido-Mesa, N., Galvez, J., A new therapeutic association to manage relapsing experimental colitis: doxycycline plus Saccharomyces boulardii. Pharmacol. Res. 97 (2015), 48–63.
153. [153] Sokol, H., Galperine, T., Kapel, N., Bourlioux, P., Seksik, P., Barbut, F., Scanzi, J., Chast, F., Batista, R., Joly, F., Joly, A.C., Collignon, A., Guery, B., Beaugerie, L., T. French grp faecal microbiota, faecal microbiota transplantation in recurrent Clostridium difficile infection: recommendations from the french group of faecal microbiota transplantation. Dig. Liver Dis. 48 (2016), 242–247.
154. [154] Mattner, J., Schmidt, F., Siegmund, B., Faecal microbiota transplantation-A clinical view. Int. J. Med. Microbiol. 306 (2016), 310–315.
155. [155] Butto, L.F., Haller, D., Dysbiosis in intestinal inflammation: cause or consequence. Int. J. Med. Microbiol. 306 (2016), 302–309.
156. [156] Gunther, C., Josenhans, C., Wehkamp, J., Crosstalk between microbiota, pathogens and the innate immune responses. Int. J. Med. Microbiol. 306 (2016), 257–265.
157. [157] Khoury, M.J., Iademarco, M.F., Riley, W.T., Precision public health for the era of precision medicine. Am. J. Prev. Med. 50 (2016), 398–401.
158. [158] Twilt, M., Precision medicine: the new era in medicine. Ebiomedicine 4 (2016), 24–25.
159. [159] Browne, H.P., Forster, S.C., Anonye, B.O., Kumar, N., Neville, B.A., Stares, M.D., Goulding, D., Lawley, T.D., Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533 (2016), 543–546.
160. [160] Lagier, J.C., Khelaifia, S., Alou, M.T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S.I., Seck, E.H., Dubourg, G., Durand, G., Mourembou, G., Guilhot, E., Togo, A., Bellali, S., Bachar, D., Cassir, N., Bittar, F., Delerce, J., Mailhe, M., Ricaboni, D., Bilen, M., Nieko, N., Badiane, N.M.D., Valles, C., Mouelhi, D., Diop, K., Million, M., Musso, D., Abrahao, J., Azhar, E.I., Bibi, F., Yasir, M., Diallo, A., Sokhna, C., Djossou, F., Vitton, V., Robert, C., Rolain, J.M., La Scola, B., Fournier, P.E., Levasseur, A., Raoult, D., Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol., 1, 2016, 16203.
161. [161] Lagier, J.C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.F., Koonin, E.V., La Scola, B., Raoult, D., Microbial culturomics: paradigm shift in the human gut microbiome study. Clin. Microbiol. Infec 18 (2012), 1185–1193.
162. [162] Samb-Ba, B., Mazenot, C., Gassama-Sow, A., Dubourg, G., Richet, H., Hugon, P., Lagier, J.C., Raoult, D., Fenollar, F., MALDI-TOF identification of the human gut microbiome in people with and without diarrhea in senegal. Plos One, 9, 2014.
163. [163] Mishra, A.K., Gimenez, G., Lagier, J.-C., Robert, C., Raoult, D., Fournier, P.-E., Genome sequence and description of Alistipes senegalensis sp nov. Stand. Genomic Sci. 6 (2012), 304–314.
164. [164] Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M.J., Valles-Colomer, M., Vandeputte, D., Tito, R.Y., Chaffron, S., Rymenans, L., Verspecht, C., De Sutter, L., Lima-Mendez, G., D'hoe, K., Jonckheere, K., Homola, D., Garcia, R., Tigchelaar, E.F., Eeckhaudt, L., Fu, J., Henckaerts, L., Zhernakova, A., Wijmenga, C., Raes, J., Population-level analysis of gut microbiome variation. Science 352 (2016), 560–564.
165. [165] Li, S.S., Zhu, A., Benes, V., Costea, P.I., Hercog, R., Hildebrand, F., Huerta-Cepas, J., Nieuwdorp, M., Salojärvi, J., Voigt, A.Y., Zeller, G., Sunagawa, S., de Vos, W.M., Bork, P., Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352 (2016), 586–589.
166. [166] Maldonado-Lobon, J.A., Gil-Campos, M., Maldonado, J., Lopez-Huertas, E., Flores-Rojas, K., Valero, A.D., Rodriguez-Benitez, M.V., Banuelos, O., Lara-Villoslada, F., Fonolla, J., Olivares, M., Long-term safety of early consumption of Lactobacillus fermentum CECT5716: a 3-year follow-up of a randomized controlled trial. Pharmacol. Res. 95–96 (2015), 12–19.
167. [167] Vazquez-Fresno, R., Llorach, R., Marinic, J., Tulipani, S., Garcia-Aloy, M., Espinosa-Martos, I., Jimenez, E., Rodriguez, J.M., Andres-Lacueva, C., Urinary metabolomic fingerprinting after consumption of a probiotic strain in women with mastitis. Pharmacol. Res. 87 (2014), 160–165.